CVR number 19703444
Industry 46.9000 Non-specialised wholesale trade

PROBODY MEDICAL ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  2.1% 2.1% 2.1% 2.1% 2.1%  
Bankruptcy risk  5.2% 4.7% 4.5% 5.1% 4.1%  
Credit score (0-100)  44 45 45 42 48  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  30.5 155 50.3 17.8 20.2  
EBITDA  26.9 153 50.0 17.8 18.6  
EBIT  23.3 115 33.6 15.6 18.3  
Pre-tax profit (PTP)  12.2 108.9 26.5 15.1 12.5  
Net earnings  10.0 105.1 23.4 11.1 12.0  
Pre-tax profit without non-rec. items  12.2 109 26.5 15.1 12.5  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  492 467 467 474 529  
Shareholders equity total  125 125 125 125 125  
Interest-bearing liabilities  3,106 3,116 3,411 3,435 3,447  
Balance sheet total (assets)  3,646 3,804 3,821 3,805 3,821  
Net Debt  2,995 2,670 3,108 3,195 3,202  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  30.5 155 50.3 17.8 20.2  
Gross profit growth  -87.0% 407.0% -67.4% -64.6% 13.2%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,646 3,804 3,821 3,805 3,821  
Balance sheet change%  -0.7% 4.4% 0.4% -0.4% 0.4%  
Added value  26.9 152.7 50.0 32.0 18.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  18 -63 -16 5 55  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  76.4% 74.6% 66.8% 87.3% 90.4%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.6% 3.1% 0.9% 0.4% 0.5%  
ROI %  0.7% 3.5% 1.0% 0.4% 0.5%  
ROE %  8.0% 84.1% 18.7% 8.9% 9.6%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  3.6% 3.4% 3.4% 3.4% 3.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  11,118.9% 1,747.9% 6,212.5% 17,913.7% 17,236.4%  
Gearing %  2,484.8% 2,492.8% 2,728.7% 2,748.3% 2,757.7%  
Net interest  0 0 0 0 0  
Financing costs %  0.4% 0.2% 0.2% 0.0% 0.2%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.1 0.3 8.7 13.1 9.9  
Current Ratio  2.0 1.9 19.0 21.2 20.3  
Cash and cash equivalent  111.5 446.3 303.2 240.5 244.9  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,546.3 1,570.3 3,177.9 3,174.2 3,130.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0